Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response

Laura Lavinia Travaini, Silvia Melania Baio, Marta Cremonesi, Concetta De Cicco, Mahila Ferrari, Giuseppe Trifirò, Gennaro Prisco, Giuseppe Viale, Marco Angelo Colleoni, Davide Radice, Gregory B. Sivolapenko, Giovanni Paganelli

Research output: Contribution to journalArticlepeer-review

Abstract

Mammoscintigraphy (MMS) has been indicated as a useful tool in predicting response to therapy in cancer. However, contrasting results have been reported in the literature for breast cancer patients. The aim of this study was to explore the role of MMS in locally advanced breast cancer (LABC) patients. Fifty-one patients affected by LABC and scheduled for neoadjuvant therapy were enrolled. Breast tumor status was evaluated at baseline, during therapy and at the completion of therapy by radiological techniques and by MMS. Pre-therapy (MMS1) and post-therapy MIBI (2-methoxyisobutilysonitrile) images (MMS2-3) were analyzed. MMS1 was performed in all pts, 41 carried out MMS2 and 27 had MMS3. Tumor uptake and washout in MMS1 did not show any correlation with the therapy response. The absence of any association between tumor uptake and washout with respect to therapy response suggests that MMS is not a reliable technique to predict therapy response in LABC.

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalBreast
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 2007

Keywords

  • Adjuvant therapy
  • Breast tumor
  • Mammoscintigraphy
  • Multidrug resistance
  • Therapy response

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response'. Together they form a unique fingerprint.

Cite this